Mon panier

Human PTK7 / CCK4 Protein, His Tag, low endotoxin (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
PT7-H52H3-100ug
$435.00
PT7-H52H3-1mg
$3100.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    PTK7, CCK4, CCK-4, Tyrosine-protein kinase-like 7, Protein-tyrosine kinase 7, Protein-tyrosine kinase 7

  • Source

    Human PTK7, His Tag (PT7-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ala 31 - Thr 704 (Accession # Q13308-1).

    Predicted N-terminus: Ala 31

    Request for sequence
  • Molecular Characterization

    PTK7 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 76.5 kDa. The protein migrates as 100-125 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    PTK7 SDS-PAGE

    Human PTK7, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    PTK7 SEC-MALS

    The purity of Human PTK7, His Tag (Cat. No. PT7-H52H3) is more than 95% and the molecular weight of this protein is around 90-110 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     PTK7 ELISA

    Immobilized Human PTK7, His Tag (Cat. No. PT7-H52H3) at 1 μg/mL (100 μL/well) can bind Cofetuzumab Pelidotin with a linear range of 0.2-4 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     PTK7 SPR

    Cofetuzumab captured on Protein A Chip can bind Human PTK7, His Tag (Cat. No. PT7-H52H3) with an affinity constant of 5.86 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

  • 1***62022-08-09
    J'aime
    Validated by SPR, measured monovalent affinity, anti-human FC chip, loaded diluted antibody, added diluted Folate R, His tag, with the affinity constant of 4 nM.

Introduction de fond

PTK7, highly expressed in lung, liver, pancreas, kidney, placenta and melanocytes. Weakly expressed in thyroid gland, ovary, brain, heart and skeletal muscle. Also expressed in erythroleukemia cells. Inactive tyrosine kinase involved in Wnt signaling pathway. Component of both the non-canonical (also known as the Wnt/planar cell polarity signaling) and the canonical Wnt signaling pathway. Functions in cell adhesion, cell migration, cell polarity, proliferation, actin cytoskeleton reorganization and apoptosis. Has a role in embryogenesis, epithelial tissue organization and angiogenesis.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Protein-tyrosine kinase 7

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    8 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte